Ohning G V, Walsh J H, Pisegna J R, Murthy A, Barth J, Kovacs T O G
Research and Medical Services, Department of Veteran Affairs, VA GLAHS-West Los Angeles Healthcare Center, and the Department of Medicine, School of Medicine, University of California, Los Angeles, CA 90073, USA.
Aliment Pharmacol Ther. 2003 May 1;17(9):1109-14. doi: 10.1046/j.1365-2036.2003.01573.x.
Peptone meal-stimulated gastric acid output is considered to be a reliable means to evaluate drug-mediated inhibition of stimulated gastric acid output, an important measure of the efficacy of the agents--such as proton pump inhibitors--used to treat acid-related disorders.
To compare the initial and overall inhibitory effects on peptone meal-stimulated gastric acid secretion of rabeprazole and omeprazole, 20 mg, in Helicobacter pylori-negative subjects on the first and eighth days of treatment.
Healthy volunteers (n = 27) were randomized in a single-centre, double-blind, double-dummy, 2 x 2 cross-over study. Subjects received an oral dose of rabeprazole or omeprazole, 20 mg once daily, for 8 days. After a 2-4-week washout period, subjects were crossed over to receive the other medication for 8 days. Peptone meal-stimulated gastric acid secretion was measured at hours 11 and 23 at baseline and on days 1 and 8 of treatment.
On days 1 and 8, rabeprazole demonstrated a significantly greater inhibition of peptone meal-stimulated gastric acid secretion compared with omeprazole at all time points (P < 0.03). Median values of steady-state inhibition on day 1 were statistically significant at hour 23 (rabeprazole 100% vs. omeprazole 74%, P < 0.02).
Rabeprazole, 20 mg, demonstrated superior control of peptone meal-stimulated gastric acid secretion compared with omeprazole, 20 mg, after the first dose and after the eighth daily dose. Rabeprazole achieved a more rapid onset of acid inhibition and a greater steady-state reduction in peptone meal-stimulated gastric acid secretion.
蛋白胨餐刺激的胃酸分泌被认为是评估药物介导的刺激胃酸分泌抑制作用的可靠方法,这是用于治疗酸相关疾病的药物(如质子泵抑制剂)疗效的一项重要指标。
比较雷贝拉唑和20毫克奥美拉唑对幽门螺杆菌阴性受试者在治疗第1天和第8天对蛋白胨餐刺激的胃酸分泌的初始和总体抑制作用。
健康志愿者(n = 27)在单中心、双盲、双模拟、2×2交叉研究中随机分组。受试者每日口服一次20毫克雷贝拉唑或奥美拉唑,共8天。经过2 - 4周的洗脱期后,受试者交叉接受另一种药物治疗8天。在基线以及治疗第1天和第8天的第11小时和第23小时测量蛋白胨餐刺激的胃酸分泌。
在第1天和第8天,雷贝拉唑在所有时间点对蛋白胨餐刺激的胃酸分泌的抑制作用均显著大于奥美拉唑(P < 0.03)。第1天稳态抑制的中位数在第23小时具有统计学意义(雷贝拉唑100% 对奥美拉唑74%,P < 0.02)。
与20毫克奥美拉唑相比,20毫克雷贝拉唑在首剂和每日第8剂后对蛋白胨餐刺激的胃酸分泌具有更好的控制作用。雷贝拉唑实现了更快的酸抑制起效时间和更大程度的蛋白胨餐刺激胃酸分泌的稳态降低。